• Home
  • What is Soprobec?
  • Why choose Soprobec?
  • Soprobec acquisition cost
  • Support for payers
  • Support for patients
  • Prescribing information & AE reporting
  • Summary of product characteristics
  • Patient information leaflet
  • References
  • You are currently browsing the Tiogiva blog archives for May, 2019.

  • Pages

    • Coming soon
    • HCP
    • landing-page
    • Maintenance
    • Patient
  • Archives

    • May 2019
  • Categories

    • Uncategorized (1)

Clenil® is a registered trademark of Chiesi Ltd. VolumaticTM is a trademark of GlaxoSmithKline UK Ltd.

PIP codes: Soprobec 50 mcg/actuation - 4098620, Soprobec 100 mcg/actuation- 4098638, Soprobec 200 mcg/actuation - 4098646, Soprobec 250 mcg/actuation - 4098653.

© 2021 Glenmark Pharmaceuticals Europe Ltd. All rights reserved. Date of preparation: February 2021 PP-UK-SOP-0035 V5

Adverse events should be reported.

Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.

Adverse events should also be reported to medical_information@glenmarkpharma.com

or call 0800 458 0383.

  • Terms of use
  • About Glenmark
  • Contact us

By clicking this link, you are leaving the Tiogiva website and entering a third party website. Glenmark Pharmaceuticals has no control over the content and management of third party websites and cannot be held responsible or liable for this. Please check that the content of the website you are about to visit is suitable for you, and that you are the intended audience. It is recommended that you carefully read the legal notices and privacy and cookie policies of third party websites before accessing them.

If you wish to leave the site, please continue, or stay on this page.

By clicking this link, you are leaving the Tiogiva website and entering a third party website. Glenmark Pharmaceuticals has no control over the content and management of third party websites and cannot be held responsible or liable for this. Please check that the content of the website you are about to visit is suitable for you, and that you are the intended audience. It is recommended that you carefully read the legal notices and privacy and cookie policies of third party websites before accessing them.

If you wish to leave the site, please continue, or stay on this page.

By clicking this link, you are leaving the Tiogiva website and entering a third party website. Glenmark Pharmaceuticals has no control over the content and management of third party websites and cannot be held responsible or liable for this. Please check that the content of the website you are about to visit is suitable for you, and that you are the intended audience. It is recommended that you carefully read the legal notices and privacy and cookie policies of third party websites before accessing them.

If you wish to leave the site, please continue, or stay on this page.

By clicking this link, you are leaving the Tiogiva website and entering a third party website. Glenmark Pharmaceuticals has no control over the content and management of third party websites and cannot be held responsible or liable for this. Please check that the content of the website you are about to visit is suitable for you, and that you are the intended audience. It is recommended that you carefully read the legal notices and privacy and cookie policies of third party websites before accessing them.

If you wish to leave the site, please continue, or stay on this page.

By clicking this link, you are leaving the Tiogiva website and entering a third party website. Glenmark Pharmaceuticals has no control over the content and management of third party websites and cannot be held responsible or liable for this. Please check that the content of the website you are about to visit is suitable for you, and that you are the intended audience. It is recommended that you carefully read the legal notices and privacy and cookie policies of third party websites before accessing them.

If you wish to leave the site, please continue, or stay on this page.

By clicking this link, you are leaving the Tiogiva website and entering a third party website. Glenmark Pharmaceuticals has no control over the content and management of third party websites and cannot be held responsible or liable for this. Please check that the content of the website you are about to visit is suitable for you, and that you are the intended audience. It is recommended that you carefully read the legal notices and privacy and cookie policies of third party websites before accessing them.

If you wish to leave the site, please continue, or stay on this page.

By clicking this link, you are leaving the Tiogiva website and entering a third party website. Glenmark Pharmaceuticals has no control over the content and management of third party websites and cannot be held responsible or liable for this. Please check that the content of the website you are about to visit is suitable for you, and that you are the intended audience. It is recommended that you carefully read the legal notices and privacy and cookie policies of third party websites before accessing them.

If you wish to leave the site, please continue, or stay on this page.

By clicking this link, you are leaving the Tiogiva website and entering a third party website. Glenmark Pharmaceuticals has no control over the content and management of third party websites and cannot be held responsible or liable for this. Please check that the content of the website you are about to visit is suitable for you, and that you are the intended audience. It is recommended that you carefully read the legal notices and privacy and cookie policies of third party websites before accessing them.

If you wish to leave the site, please continue, or stay on this page.